China Shineway Pharmaceutical Group Limited (HKG:2877)
9.20
+0.56 (6.48%)
At close: Mar 27, 2026
HKG:2877 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 7,189 | 6,140 | 5,889 | 5,026 | 4,206 |
Short-Term Investments | - | 4.48 | 4.02 | 3.69 | 4.32 |
Trading Asset Securities | 376.64 | 350.02 | 20 | 20.23 | - |
Cash & Short-Term Investments | 7,566 | 6,495 | 5,913 | 5,050 | 4,210 |
Cash Growth | 16.49% | 9.84% | 17.08% | 19.96% | 6.63% |
Accounts Receivable | 1,000 | 1,202 | 1,260 | 975.06 | 825.18 |
Other Receivables | - | 66.81 | 63.92 | 67.48 | 40.87 |
Receivables | 1,000 | 1,269 | 1,324 | 1,043 | 866.05 |
Inventory | 691.3 | 813.19 | 897.71 | 657.66 | 587.96 |
Other Current Assets | 47.16 | 22 | 19.94 | 32.01 | 35.06 |
Total Current Assets | 9,304 | 8,599 | 8,155 | 6,782 | 5,699 |
Property, Plant & Equipment | 1,249 | 1,219 | 1,205 | 1,217 | 1,252 |
Goodwill | 165.96 | 165.96 | 165.96 | 165.96 | 165.96 |
Other Intangible Assets | 15.72 | 23.32 | 32.79 | 47.35 | 66.43 |
Long-Term Deferred Tax Assets | 42.7 | 34.33 | 15.23 | 19.22 | 20.47 |
Total Assets | 10,777 | 10,042 | 9,574 | 8,232 | 7,204 |
Accounts Payable | 340.03 | 402.96 | 484.79 | 308.75 | 228.62 |
Accrued Expenses | 13.78 | 1,199 | 1,121 | 856.76 | 483.21 |
Short-Term Debt | 325.05 | 330 | 300 | - | - |
Current Portion of Leases | 9.06 | 8.27 | 0.97 | 6.53 | 7.59 |
Current Income Taxes Payable | 60.22 | 84.27 | 105.91 | 107.79 | 65.1 |
Current Unearned Revenue | 221.86 | 101.75 | 127.4 | 165.22 | 117.05 |
Other Current Liabilities | 1,540 | 323.67 | 294.13 | 220.54 | 196.81 |
Total Current Liabilities | 2,510 | 2,450 | 2,434 | 1,666 | 1,098 |
Long-Term Leases | 0.79 | 8.26 | 0.36 | 0.91 | 7.32 |
Long-Term Unearned Revenue | 106.24 | 81.85 | 88.89 | 163.99 | 171.59 |
Long-Term Deferred Tax Liabilities | 98.02 | 34.52 | 16.26 | 18.84 | 25.19 |
Total Liabilities | 2,715 | 2,575 | 2,539 | 1,849 | 1,302 |
Common Stock | 87.66 | 87.66 | 87.66 | 87.66 | 87.66 |
Additional Paid-In Capital | - | 422.14 | 422.14 | 422.14 | 422.14 |
Retained Earnings | - | 7,452 | 7,020 | 6,368 | 5,879 |
Comprehensive Income & Other | 7,974 | -494.89 | -494.89 | -494.89 | -487.32 |
Shareholders' Equity | 8,062 | 7,467 | 7,035 | 6,383 | 5,901 |
Total Liabilities & Equity | 10,777 | 10,042 | 9,574 | 8,232 | 7,204 |
Total Debt | 334.9 | 346.53 | 301.33 | 7.44 | 14.91 |
Net Cash (Debt) | 7,231 | 6,148 | 5,611 | 5,043 | 4,195 |
Net Cash Growth | 17.61% | 9.56% | 11.28% | 20.21% | 17.97% |
Net Cash Per Share | 9.59 | 8.14 | 7.43 | 6.68 | 5.56 |
Filing Date Shares Outstanding | 752.45 | 755.4 | 755.4 | 755.4 | 755.4 |
Total Common Shares Outstanding | 752.45 | 755.4 | 755.4 | 755.4 | 755.4 |
Working Capital | 6,794 | 6,149 | 5,721 | 5,117 | 4,601 |
Book Value Per Share | 10.71 | 9.88 | 9.31 | 8.45 | 7.81 |
Tangible Book Value | 7,880 | 7,278 | 6,836 | 6,169 | 5,669 |
Tangible Book Value Per Share | 10.47 | 9.63 | 9.05 | 8.17 | 7.50 |
Machinery | - | 1,494 | 1,489 | 1,438 | 1,392 |
Construction In Progress | - | 195.51 | 117.68 | 193.06 | 130.17 |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.